8-K: Neurocrine Biosciences Reports Strong Q3 2024 Results, Raises INGREZZA Sales Guidance and Announces Share Repurchase Plan

Neurocrine Biosciences announced strong third-quarter 2024 financial results, highlighted by a 26% year-over-year increase in INGREZZA sales, and raised its full-year sales guidance while also authorizing a $300 million share repurchase program.

Summary

• Neurocrine Biosciences reported its financial results for the third quarter of 2024, ending September 30, 2024.
• The company's net product sales for INGREZZA reached $613 million, a 26% increase compared to the same quarter in 2023.
• Total revenues for the quarter were $622.1 million, up from $498.8 million in the prior year.
• GAAP net income for the quarter was $129.8 million, or $1.24 per diluted share, compared to $83.1 million, or $0.82 per diluted share, in Q3 2023.
• Non-GAAP net income was $189.2 million, or $1.81 per diluted share, compared to $156.1 million, or $1.54 per diluted share, in the same period last year.
• The company has raised its 2024 net product sales guidance for INGREZZA to between $2.30 and $2.32 billion.
• A $300 million share repurchase plan has been authorized by the board, with an accelerated share repurchase transaction planned.
• The company's cash, cash equivalents, and marketable securities totaled approximately $1.9 billion as of September 30, 2024.
• The company's R&D expenses increased due to investments in muscarinic compounds, gene therapy programs, and second-generation VMAT2 inhibitors.
• SG&A expenses increased due to investments in crinecerfont-related activities and the expansion of the INGREZZA sales team.
• The company expects to advance NBI-1117568 into Phase 3 development in the first half of 2025.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to strong sales growth, increased guidance, and a share repurchase program. The negative aspects, such as the termination of license agreements, are balanced by the overall positive financial performance and future outlook.

Positives

• INGREZZA sales showed strong growth, increasing by 26% year-over-year.
• The company raised its full-year sales guidance for INGREZZA, indicating confidence in future performance.
• The board authorized a $300 million share repurchase plan, signaling confidence in the company's value.
• The company has a strong cash position of approximately $1.9 billion.
• Positive topline data was announced for the Phase 2 study of NBI-1117568.
• The company is advancing NBI-1117568 into Phase 3 development in the first half of 2025.

Negatives

• The ERUDITE Phase 2 study of luvadaxistat did not meet its primary endpoint.
• The company terminated license agreements for luvadaxistat and NBI-827104.
• The company incurred a $17 million loss from changes in fair values of equity investments in Q3 2024, although this was an improvement from a $40 million loss in Q3 2023.

Risks

• The company's future financial and operating performance is subject to risks and uncertainties.
• The commercialization of INGREZZA carries inherent risks.
• There are risks that the crinecerfont New Drug Applications may not obtain regulatory approval or may be delayed.
• The company is dependent on third parties for development, manufacturing, and commercialization activities.
• Clinical development activities may not be successful or may be delayed.
• The company faces competition from other therapies and products.
• There are risks associated with government and third-party regulatory and/or policy efforts.

Future Outlook

The company has raised its 2024 net product sales guidance for INGREZZA to $2.30 $2.32 billion and expects to advance NBI-1117568 into Phase 3 development in the first half of 2025. The company also anticipates the launch of crinecerfont.

Management Comments

• Kyle W. Gano, Ph.D., Chief Executive Officer, stated that the company is confident in its ability to help more patients due to continued INGREZZA growth, the FDA Priority Review for crinecerfont, a deep neuroscience pipeline, and a strong balance sheet.
• William Rastetter, Chairman of the Board, said the share repurchase authorization reflects the Board's confidence in Neurocrine's significant value creation potential and preserves flexibility for sustained growth.

Industry Context

This announcement reflects the continued growth in the neuroscience-focused biopharmaceutical sector, with Neurocrine's strong performance in INGREZZA sales highlighting the demand for treatments in tardive dyskinesia and Huntington's disease. The company's pipeline and strategic collaborations position it well within the competitive landscape.

Comparison to Industry Standards

• Neurocrine's 26% year-over-year growth in INGREZZA sales is strong compared to the average growth rates of other pharmaceutical companies in the neuroscience space, which typically range from 5-15% for established products.
• The company's cash position of $1.9 billion is robust, providing a solid foundation for future investments and acquisitions, which is comparable to other large-cap biotech companies.
• The share repurchase program is a common strategy among mature biotech companies with strong cash flow, similar to companies like Amgen and Gilead Sciences.
• The termination of the luvadaxistat and NBI-827104 license agreements is not uncommon in the pharmaceutical industry, where clinical trial failures and strategic shifts often lead to pipeline adjustments, similar to decisions made by companies like Biogen and Vertex Pharmaceuticals.
• The company's focus on neuroscience and its pipeline of novel therapies is consistent with the industry trend towards developing treatments for complex neurological disorders, similar to companies like Sage Therapeutics and Acadia Pharmaceuticals.

Management Changes

Stakeholder Impact

• Shareholders will benefit from the share repurchase program and the increased value of the company.
• Employees may see increased job security and opportunities due to the company's growth.
• Patients will benefit from the continued development and commercialization of new treatments.
• Suppliers and partners will benefit from the company's continued growth and investment.

Next Steps

• The company intends to enter into a $300 million accelerated share repurchase transaction.
• The company expects to advance NBI-1117568 into Phase 3 development in the first half of 2025.
• The company will continue pre-launch commercial activities for crinecerfont.
• The company will continue to invest in its pipeline and commercial initiatives.

Key Dates

Keywords

Neurocrine Biosciences, INGREZZA, Valbenazine, Tardive Dyskinesia, Huntingtons Disease, Crinecerfont, Share Repurchase, Financial Results, Pharmaceutical, Biotechnology